OPTIMA Trial: Prosigna-Guided Chemotherapy De-Escalation in High-Risk Breast Cancer

Dr. Zunairah Shah outlines the phase 3 OPTIMA trial design, showing how Prosigna-guided testing informs chemotherapy decisions in high-risk breast cancer.

Dr. Zunairah Shah discusses OPTIMA data showing comparable outcomes with and without chemotherapy in low-risk, Prosigna-guided patients with breast cancer.

Dr. Zunairah Shah explains how she uses shared decision-making and discusses real-world access to Prosigna genomic testing in high-risk breast cancer.